Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy

Morgan R Godin, Preeya K Gupta Department of Ophthalmology, Division of Cornea and Refractive Surgery, Duke University Eye Center, Durham, NC, USA Abstract: A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry eye patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Godin MR, Gupta PK
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	dry eye ocular surface lifitegrast OPUS-1 OPUS-2 OPUS-3 SONATA LFA-1 ICAM-1 OSDI ODS VAS cyclosporine Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/eccfef0b80344d40b251c2575f854896
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:eccfef0b80344d40b251c2575f854896
record_format	dspace
spelling	oai:doaj.org-article:eccfef0b80344d40b251c2575f8548962021-12-02T02:48:44ZLifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy1177-5483https://doaj.org/article/eccfef0b80344d40b251c2575f8548962017-05-01T00:00:00Zhttps://www.dovepress.com/lifitegrast-ophthalmic-solution-in-the-treatment-of-signs-and-symptoms-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Morgan R Godin, Preeya K Gupta Department of Ophthalmology, Division of Cornea and Refractive Surgery, Duke University Eye Center, Durham, NC, USA Abstract: A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry eye patients. Lifitegrast is an integrin antagonist that decreases inflammation on the ocular surface, thereby improving dry eye disease (DED). Through a series of prospective, multicenter, randomized, masked, placebo-controlled studies in >2,000 patients total, lifitegrast was shown to be effective for improvement in both the signs and symptoms of DED. A subsequent study focused on the safety profile of lifitegrast and demonstrated that the majority of adverse events were mild and resolved over time. Lifitegrast is now available for use in clinical practice. Keywords: OPUS-1, OPUS-2, OPUS-3, SONATA, LFA-1, ICAM-1, OSDI, ocular surfaceGodin MRGupta PKDove Medical Pressarticledry eyeocular surfacelifitegrastOPUS-1OPUS-2OPUS-3SONATALFA-1ICAM-1OSDIODSVAScyclosporineOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 951-957 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	dry eye ocular surface lifitegrast OPUS-1 OPUS-2 OPUS-3 SONATA LFA-1 ICAM-1 OSDI ODS VAS cyclosporine Ophthalmology RE1-994
spellingShingle	dry eye ocular surface lifitegrast OPUS-1 OPUS-2 OPUS-3 SONATA LFA-1 ICAM-1 OSDI ODS VAS cyclosporine Ophthalmology RE1-994 Godin MR Gupta PK Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
description	Morgan R Godin, Preeya K Gupta Department of Ophthalmology, Division of Cornea and Refractive Surgery, Duke University Eye Center, Durham, NC, USA Abstract: A new topical ophthalmic medication, lifitegrast 5%, was recently approved by the US Food and Drug Administration for use in dry eye patients. Lifitegrast is an integrin antagonist that decreases inflammation on the ocular surface, thereby improving dry eye disease (DED). Through a series of prospective, multicenter, randomized, masked, placebo-controlled studies in >2,000 patients total, lifitegrast was shown to be effective for improvement in both the signs and symptoms of DED. A subsequent study focused on the safety profile of lifitegrast and demonstrated that the majority of adverse events were mild and resolved over time. Lifitegrast is now available for use in clinical practice. Keywords: OPUS-1, OPUS-2, OPUS-3, SONATA, LFA-1, ICAM-1, OSDI, ocular surface
format	article
author	Godin MR Gupta PK
author_facet	Godin MR Gupta PK
author_sort	Godin MR
title	Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
title_short	Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
title_full	Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
title_fullStr	Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
title_full_unstemmed	Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
title_sort	lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/eccfef0b80344d40b251c2575f854896
work_keys_str_mv	AT godinmr lifitegrastophthalmicsolutioninthetreatmentofsignsandsymptomsofdryeyediseasedesigndevelopmentandplaceintherapy AT guptapk lifitegrastophthalmicsolutioninthetreatmentofsignsandsymptomsofdryeyediseasedesigndevelopmentandplaceintherapy
_version_	1718402135483219968

Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy

Ejemplares similares